These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 29325642)

  • 21. HEART UK consensus statement on Lipoprotein(a): A call to action.
    Cegla J; Neely RDG; France M; Ferns G; Byrne CD; Halcox J; Datta D; Capps N; Shoulders C; Qureshi N; Rees A; Main L; Cramb R; Viljoen A; Payne J; Soran H;
    Atherosclerosis; 2019 Dec; 291():62-70. PubMed ID: 31704552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.
    Nordestgaard BG; Langsted A
    J Lipid Res; 2016 Nov; 57(11):1953-1975. PubMed ID: 27677946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research.
    Kamstrup PR; Neely RDG; Nissen S; Landmesser U; Haghikia A; Costa-Scharplatz M; Abbas C; Nordestgaard BG
    Eur J Prev Cardiol; 2024 May; 31(7):903-914. PubMed ID: 38253342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipoprotein(a) and Cardiovascular Diseases　- Revisited.
    Jang AY; Han SH; Sohn IS; Oh PC; Koh KK
    Circ J; 2020 May; 84(6):867-874. PubMed ID: 32336721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The re-emergence of lipoprotein(a) in a broader clinical arena.
    Tsimikas S
    Prog Cardiovasc Dis; 2016; 59(2):135-144. PubMed ID: 27497506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis.
    Capoulade R; Chan KL; Yeang C; Mathieu P; Bossé Y; Dumesnil JG; Tam JW; Teo KK; Mahmut A; Yang X; Witztum JL; Arsenault BJ; Després JP; Pibarot P; Tsimikas S
    J Am Coll Cardiol; 2015 Sep; 66(11):1236-1246. PubMed ID: 26361154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is Lipoprotein(a) Clinically Actionable with Today's Evidence? The Answer is Yes.
    Ma GS; Chiou TT; Wilkinson MJ
    Curr Cardiol Rep; 2023 Oct; 25(10):1175-1187. PubMed ID: 37632608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease.
    Nsaibia MJ; Mahmut A; Boulanger MC; Arsenault BJ; Bouchareb R; Simard S; Witztum JL; Clavel MA; Pibarot P; Bossé Y; Tsimikas S; Mathieu P
    J Intern Med; 2016 Nov; 280(5):509-517. PubMed ID: 27237700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Riskier Lipid: What Is on the HORIZON for Lipoprotein (a) and Should There Be Lp(a) Screening for All?
    Nicholls SJ; Bubb KJ
    Curr Cardiol Rep; 2021 Jul; 23(8):97. PubMed ID: 34196823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipoprotein(a) in Patients Undergoing Transcatheter Aortic Valve Replacement.
    Ma GS; Wilkinson MJ; Reeves RR; Yeang C; DeMaria AN; Cotter B; Patel M; Mahmud E; Tsimikas S
    Angiology; 2019 Apr; 70(4):332-336. PubMed ID: 30700108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Not Available].
    Kronenberg F
    Praxis (Bern 1994); 2017 Aug; 106(17):949-954. PubMed ID: 28830318
    [No Abstract]   [Full Text] [Related]  

  • 32. Role of lipoprotein (a) and LPA KIV2 repeat polymorphism in bicuspid aortic valve stenosis and calcification: a proof of concept study.
    Sticchi E; Giusti B; Cordisco A; Gori AM; Sereni A; Sofi F; Mori F; Colonna S; Fugazzaro MP; Pepe G; Nistri S; Marcucci R
    Intern Emerg Med; 2019 Jan; 14(1):45-50. PubMed ID: 30099661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipoprotein(a): Are we ready for large-scale clinical trials?
    Zheng S; Fang G; Du J; Dong J
    Int J Cardiol; 2024 Sep; 410():132236. PubMed ID: 38848771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis.
    Yeang C; Wilkinson MJ; Tsimikas S
    Curr Opin Cardiol; 2016 Jul; 31(4):440-50. PubMed ID: 27205885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipoprotein(a) is a risk factor for aortic and mitral valvular stenosis in peripheral arterial disease.
    Hojo Y; Kumakura H; Kanai H; Iwasaki T; Ichikawa S; Kurabayashi M
    Eur Heart J Cardiovasc Imaging; 2016 May; 17(5):492-7. PubMed ID: 26758409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Fetuin-A, Lp(a), matrix gla protein and macrophage density on calcific aortic valve disease: a clinical study.
    Liu C; Liu H; Xie T
    Lipids Health Dis; 2022 Jan; 21(1):14. PubMed ID: 35065626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lp(a) - an overlooked risk factor.
    Laffin LJ; Nissen SE
    Trends Cardiovasc Med; 2024 Apr; 34(3):193-199. PubMed ID: 36681362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis.
    Tsimikas S
    Circ Res; 2019 Feb; 124(3):405-415. PubMed ID: 30702993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autotaxin Derived From Lipoprotein(a) and Valve Interstitial Cells Promotes Inflammation and Mineralization of the Aortic Valve.
    Bouchareb R; Mahmut A; Nsaibia MJ; Boulanger MC; Dahou A; Lépine JL; Laflamme MH; Hadji F; Couture C; Trahan S; Pagé S; Bossé Y; Pibarot P; Scipione CA; Romagnuolo R; Koschinsky ML; Arsenault BJ; Marette A; Mathieu P
    Circulation; 2015 Aug; 132(8):677-90. PubMed ID: 26224810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipoprotein(a), a Lethal Player in Calcific Aortic Valve Disease.
    Hu J; Lei H; Liu L; Xu D
    Front Cell Dev Biol; 2022; 10():812368. PubMed ID: 35155427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.